Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Softmax Co., Ltd (3671.T)
Tokyo, JP
Softmax Co., Ltd handles the complete spectrum of corporate system services, encompassing their development, commercialization, deployment, and ongoing support. A significant portion of their work is dedicated to creating advanced medical information systems. Their offerings within the healthcare sector are diverse, comprising web-based electronic medical record (EMR) systems, online patient ordering platforms, medical financial management software, radiology information systems, and specialized solutions for rehabilitation departments, health screening, nursing task management, and surgical units. Established in 1974, Softmax Co., Ltd's corporate headquarters are located in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.33% | -13.43% | -16.07% | -3.81% | -14.16% | -11.40% | +36.78% | +66.48% | +2.28% | +133.80% | -24.25% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+27.6% ★ Q1'26: +70.5% (vs Q1'25)
-
EPS growth Medical - Healthcare Information Services: +43.1%+19.3% Q1'26: -4.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%+5.8% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+10.7% ★ Q1'26: +9.9% (vs Q1'25)
-
ROIC Medical - Healthcare Information Services: +5.2%+16.3% ★ Q1'26: +18.0% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%+0.1% Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×3.16× ★ Q1'26: 2.59× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2017 actual |
|---|---|---|
| Revenue |
3.02B
est: 5.02B (-39.8%)
|
3.29B
est: 3.10B (+6.2%)
|
| EBITDA |
114.49M
est: 664.99M (-82.8%)
|
233.89M
est: 410.65M (-43.0%)
|
| EBIT |
67.61M
est: 634.86M (-89.4%)
|
170.75M
est: 392.05M (-56.4%)
|
| Net Income |
53.43M
est: 376.54M (-85.8%)
|
89.24M
est: 40.04M (+122.9%)
|
| SGA |
730.07M
est: 932.33M (-21.7%)
|
700.61M
est: 575.74M (+21.7%)
|
| EPS |
2.24
est: 62.77 (-96.4%)
|
3.74
est: 6.68 (-44.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Arisa Nakamura | Executive Officer | — | — |
| Chieko Shimamori | President, Chief Executive Officer & Representative Director | — | — |
| Hiroshi Ozono | Executive Officer | — | — |
| Junji Higashi | Executive Officer | — | — |
| Katsuji Saito | MD of Solutions Division & Director | — | — |
| Kazushi Shimotamari | MD of System Development Division & Director | — | — |
| Makoto Nagai | Executive Officer | — | — |
| Nobutaka Fukumori | Executive Officer | — | — |
| Tatsuhiko Nomura | MD of West Japan Business Division & Director | — | male |
| Yuki Yokooji | Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3671.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
